Steps towards medication harmonization: A look at Europe and the United States

References

• Abraham , J. 1995 . Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation , New York : St. Martin's Press .
   Google Scholar
• Alchian , A. A. and Woodward , S. 1987 . Reflections on the theory of the firm . Journal of Institutional and Theoretical Economics , 143 ( 1 ) : 110 – 136 .
   Web of Science ®Google Scholar
• Anell , A. and Willis , M. 2000 . International comparison of health care systems using resource profiles . Bulletin of the World Health Organization , 78 ( 6 ) : 770 – 778 .
   PubMed Web of Science ®Google Scholar
• Angel , J. E. 1992 . New initiatives in advertising and promotion: health care communicators respond . Food and Drug Law Journal , 47 ( 1 ) : 59 – 61 .
   Web of Science ®Google Scholar
• Arbour , M. E. 2004 . Compensation for damage caused by defective drugs: European private law between safety requirements and free-market values . European Law Journal , 10 ( 1 ) : 87 – 101 .
   Google Scholar
• Baily , M. N. 1972 . Research and development cost and returns: the pharmaceutical industry . Journal of Political Economics , 80 : 70 – 85 .
   Web of Science ®Google Scholar
• Ballance , R. , Pogany , J. Y. and Forsner , H. 1992 . “ The World's Pharmaceutical Industries: An international perspective on innovation, competition and policy ” . Prepared for United Nations Industrial Development Organization (UNIDO). (Aldershot: Edward Elgar)
   Google Scholar
• Bandhauer , K. , Curti , J. and Miller , C. 2005 . Challenges to regulatory harmonization and standard-setting: the case of environmental accounting in the US and Canada . Journal of Comparative Policy Analysis , 7 ( 2 ) : 177 – 194 .
   Google Scholar
• Berlin , H. and Jonsson , B. 1986 . International dissemination of new drugs: a comparative study of six countries . Managerial and Decision Economics , 7 : 235 – 242 .
   Web of Science ®Google Scholar
• Bogner , W. C. and Howard , T. 1995 . “ From skills to competencies: the “play-out” of resource bundles across firms ” . In Theory and Practice in Competence Based Competition: From Industry Studies to a New Theory of Competitive Dynamics , Edited by: Heene , A. , Sanchez , R. and Thomas , H. London : Pergamon Press .
   Google Scholar
• Burkhauser , R. V. and Lillard , D. R. 2005 . The contribution and potential of data harmonization for cross-national comparative research . Journal of Comparative Policy Analysis , 7 ( 4 ) : 313 – 330 .
   Google Scholar
• Burstall , M. L. 1991 . Europe after 1992. Implications for pharmaceuticals . Health Affairs , 10 ( 3 ) : 157 – 171 .
   Web of Science ®Google Scholar
• Cabiedes , L. 1995 . “ La regulación de la industria farmacéutica ” . In Regulación y competencia en la economía española 213 – 229 . IX Jornadas de Alicante sobre Economía Española, Biblioteca Civitas de Economía y Empresa, Ed. Civitas
   Google Scholar
• Clark , N. J. 1996 . Rx-to-OTC Switching – New Indications, New Opportunities , London : Pharmaceutical & Healthcare Publishing .
   Google Scholar
• Danzon , P. M. 1995 . Les effects de la réglementation des prix sur l'industrie pharmaceutique . Analyse financière , 102 : 30 – 37 .
   Google Scholar
• Danzon , P. M. 1997 . Pharmaceutical Price Regulation, National Policies versus Global Interest , Washington : AEI Press .
   Google Scholar
• Danzon , P. M. 1999 . Price Comparisons for Pharmaceuticals: A Review of U.S. and Cross-national Studies, National Policies versus Global Interest , Washington, DC : AEI Press .
   Google Scholar
• Danzon , P. M. and Pauly , M. V. 2002 . Health insurance and the growth in pharmaceutical expenditures . Journal of Law and Economics , XLV : 587 – 613 .
   Google Scholar
• Dixit , A. K. 1996 . The Making of Economic Policy, A Transaction-Cost Politics Perspective , Cambridge, MA : The MIT Press .
   Google Scholar
• Douma , S. and Scheuder , H. 1992 . Economic Approaches to Organizations , London : Prentice Hall International .
   Google Scholar
• Getzen , T. E. 1997 . Health Economics, Fundamentals and Flow of Funds , New York : John Wiley & Sons .
   Google Scholar
• Grabowski , H. G. and Vernon , J. M. 1977 . Consumer protection regulation in ethical drugs . American Economic Association , 67 ( 1 ) : 359 – 364 .
   Google Scholar
• Grabowski , H. G. and Vernon , J. M. 1983 . The Regulation of Pharmaceuticals: Benefits and Risks , Washington, DC : American Enterprise Institute .
   Google Scholar
• Gruenspecht , H. K. and Lave , L. B. 1989 . The economics of health, safety, and environmental regulation . Handbook of Industrial Organization , II : 1507 – 1551 .
   Google Scholar
• Herberts Scheinberg , I. and Walshe , J. M. 1986 . Orphan Diseases and Orphan Drugs , Manchester : Manchester University Press) .
   Google Scholar
• Hill , C. W. L. and Jones , T. M. 1992 . Stakeholder agency theory . Journal of Management Studies , 29 : 131 – 154 .
   Web of Science ®Google Scholar
• ICH Steering Committee . 1990 . Statement by the ICH Steering Committee, Tokyo available at http://www.ich.org/cache/compo/276-254-1.html
   Google Scholar
• ICH Steering Committee . 2000 . Statement on the Future of ICH available at http://www.ich.org/cache/compo/276-254-1.html
   Google Scholar
• Jacob , K. and Volkery , A. 2004 . Institutions and instruments for government self-regulation: Environmental policy integration in a cross-country perspective . Journal of Comparative Policy Analysis , 6 ( 3 ) : 291 – 309 .
   Google Scholar
• Johnstone , J. M. 1992 . Direct-to-consumer advertising: an industry perspective . Food and Drug Law Journal , 47 ( 1 ) : 63 – 68 .
   Web of Science ®Google Scholar
• Jordan , D. W. 1992 . International regulatory harmonization: a new era in prescription drug approval . Vanderbilt Journal of Transnational Law , 25 ( 3 ) : 471 – 507 .
   Google Scholar
• Kaitin , K. 1989 . Reply to understanding comparisons of drug introductions between the United States and the United Kingdom . Clinical Pharmacology and Therapeutics , 4 : 121 – 138 .
   Google Scholar
• Katz , E. M. 1993 . Europe's centralized new drug procedures: is the United States prepared to keep pace? . Food and Drug Law Journal , 48
   Web of Science ®Google Scholar
• Law , M. T. 2001 . The transaction cost origins of food and drug regulation . Working Paper , Department of Economics, Washington University, St Louis
   Google Scholar
• Ley del Medicamento, 1998, Tecnos, Madrid
   Google Scholar
• Levy , R. 1999 . “ The pharmaceutical industry: a discussion of competitive and antitrust issues in an environment of change ” . In Bureau of Economics Staff Report , Washington, DC : Federal Trade Commission .
   Google Scholar
• Liebenau , J. 1987 . Medical Science and Medical Industry , Baltimore, MD : The Johns Hopkins University Press .
   Google Scholar
• Linneman , P. 1980 . The effects of consumer safety standards: the 1973 Mattress flammability standard . Journal of Law and Economics , 23 : 461 – 479 .
   Web of Science ®Google Scholar
• Lobo , F. 1988 . El gasto publico en prestación farmacéutica . Papeles de Economía Española , 37 : 255 – 264 .
   Google Scholar
• Magat , W. A. and Moore , M. J. 1996 . Consumer product safety regulation in the United States and the United Kingdom: the case of bicycles . Rand Journal of Economics , 27 : 148 – 164 .
   Web of Science ®Google Scholar
• Manning , R. L. 1997 . Products viability and prescription drug prices in Canada and the United States . Journal of Law and Economics , XL : 203 – 243 .
   Google Scholar
• Neumann , G. R. and Nelson , J. P. 1982 . Safety regulation and firm size: effects of the coal mine health and safety act of 1969 . Journal of Law and Economics , 25 : 183 – 199 .
   Web of Science ®Google Scholar
• Onishi Mortimer , R. . Demand for prescription drugs: the effects of managed care pharmacy benefits, Working Paper 221 . presented in the Industrial Organization Seminar Economics, University of California, Berkeley, Department of Economics .
   Google Scholar
• Pigou , A. C. 1974 . Introducción a la economía , Barcelona, Editorial Ariel .
   Google Scholar
• Peltzman , S. 1973 . An evaluation of consumer protection legislation: the 1962 drug amendments . Journal of Political Economy , 81 : 1049 – 1091 .
   Web of Science ®Google Scholar
• Puig Junoy , J. 1998 . Regulación y competencia de precios en el mercado farmacéutico . Papeles de Economía Española , : 96 – 113 .
   Google Scholar
• Reichert , J. and Healy , E. 2001 . Biopharmaceuticals approved in the EU 1995 1999: a European Union-United States comparison . European Journal of Pharmaceutics and Biopharmaceutics , 51 ( 1 ) : 1 – 7 .
   PubMed Web of Science ®Google Scholar
• Robinson , J. C. 1996 . The dynamics and limits of corporate growth in health care . Health Affairs , 15 : 155 – 169 .
   Web of Science ®Google Scholar
• Rutherford , E. M. 1995 . The FDA and “privatization”– the drug approval process . Food and Drug Law Journal , 50 : 203 – 225 .
   PubMedGoogle Scholar
• Ryan , P. S. 2002 . “ Arbitraje regulado e importacion paralela de productos farmaceuticos en la Union Europea ” . Leuven : Katholieke Universiteit Leuven . Working Paper P. 1/33
   Google Scholar
• Schweitzer , S. O. 1997 . Pharmaceutical Economics and Policy , New York : Oxford University Press .
   Google Scholar
• Schweitzer , S. O. , Salehi , H. and Boling , N. 1985 . The social drug lag: an examination of pharmaceutical approval delays in Medicaid formularies . Social Science and Medicine , 10 : 1077 – 1982 .
   Google Scholar
• Schweitzer , S. O. , Schweitzer , M. E. and Souty-LeGuellec , M. J. 1996 . Is there a United States drug lag? The timing of new pharmaceutical approvals in the G-7 countries and Switzerland . Medical Care Research and Review , 53 : 162 – 178 .
   PubMed Web of Science ®Google Scholar
• Scott Morton , F. M. 1997 . The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules . Journal of Economics , 28 : 269 – 290 .
   Web of Science ®Google Scholar
• Shortell , S. M. , Gilles , R. R. and Anderson , D. A. 1994 . The new world of managed care: creating organized delivery systems . Health Affairs , 13 ( 5 ) : 46 – 64 .
   Web of Science ®Google Scholar
• Smith , M. C. 1996 . Pharmaceutical Marketing in the 21 Century , Binghamton, NY : The Haworth Press .
   Google Scholar
• Thompson , D. and Gutmann , A. 2002 . Deliberative democracy beyond process . Journal of Political Philosophy , 10 : 153 – 174 .
   Web of Science ®Google Scholar
• Whitmore , E. 1997 . Product Development Planning for the Health Care Products Regulated by the FDA , Milwaukee, WI : ASQC Quality Press .
   Google Scholar
• Williamson , O. E. 1985 . The Economic Institutions of Capitalism , Washington : Free Press .
   Google Scholar
• Williamson , Oliver E. 1999 . Public and private bureaucracies: a transaction cost economics perspective . Journal of Law, Economics, and Organization , 15 ( 1 ) : 306 – 339 .
   Web of Science ®Google Scholar